AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00523848
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT02499848
Drug: PRX302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single prostate cancer lesion injected with PRX302.
Trial: NCT01938092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01598363
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral, Day 1 and Day 10
Trial: NCT00848718
Drug: corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered PO twice a day (BID) on Days 1-3 of each 21-day cycle
Trial: NCT00824200
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamsulosin placebo
Trial: NCT01611883
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match ezetimibe orally once daily for 24 weeks.
Trial: NCT00466245
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 0.5mL subcutaneous injections, separated by 28 days
Trial: NCT02644954
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis
Trial: NCT03373877
Drug: PU-H71
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PU-H71 treatments will be administered by IV infusion on days 1, 8, and 15 of each 28-day cycle.
Trial: NCT02367651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets matching the 200 mg and 400 mg pazopanib tablets
Trial: NCT03764774
Drug: LY3463251
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT03764774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02596360
Drug: Pulmodexane® 30mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
Trial: NCT02596360
Drug: lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
Trial: NCT02021929
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02180529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04203342
Drug: Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo to treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
Trial: NCT02151851
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Active substance: Methotrexate~* Pharmaceutical form: Tablet~* Concentration: Maximum dose 10 mg per week~* Route of administration: Oral
Trial: NCT02143505
Drug: Ca plus vit D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements
Trial: NCT00611923
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take a lactose capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
Trial: NCT01080638
Drug: glycoprotein IIb/IIIa inhibitor (abciximab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
Trial: NCT03667222
Drug: minocycline topical gel
RxNorm normalized name: minocycline Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily administration of BPX-04 minocycline gel for 12 weeks
Trial: NCT01024504
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles
Trial: NCT00086684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks
Trial: NCT01113437
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.~Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE.
Trial: NCT02547428
Drug: CTN SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTN SR tablets, daily, Orally.
Trial: NCT02547428
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching-placebo tablets daily, orally.
Trial: NCT01056783
Drug: OC000459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OC000459 100mg, twice daily, tablet
Trial: NCT01056783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to match OC000459 tablets, twice daily
Trial: NCT00381082
Drug: 1) MOOV Head Lice Treatment (Ego Pharmaceutical).
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00381082
Drug: 3) KP24 Medicated Foam (Nelson Laboratories)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04651855
Drug: Mesenchymal stem cells isolated from Wharton's jelly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal administration of mesenchymal stem cells
Trial: NCT04070001
Drug: 400 Mg Ibuprofen
RxNorm normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-dose 400-mg ibuprofen 1-hour before elastomeric separator placement
Trial: NCT02462590
Drug: L. rhamnosus GG - Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
Trial: NCT04444011
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antibiotic
Trial: NCT01185678
Drug: Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles.
Trial: NCT02745431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00406367
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
Trial: NCT04022057
Drug: Dextrose 5
RxNorm normalized name: Dextrose 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham Injection
Trial: NCT04483830
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an oral dose of 2 capsules each day for 21 days
Trial: NCT01412567
Drug: Vaccine+Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS placebo intramuscularly immediately after birth
Trial: NCT00702767
Drug: INTRALIPIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INTRAVENOUS FAT EMULSIONS
Trial: NCT01567774
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: os, 10 mg, once per day, for 30 days
Trial: NCT02962492
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
Trial: NCT01702623
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01591135
Drug: Paclitaxel plus 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ﬂuorouracil 300 mg/m2, d1-4, continuous infusion for 96 hours and paclitaxel 50 mg/m2 over 3 hours, d1 (week 1, week 2, week 3, week 4 and week 5); 5-ﬂuorouracil 600 mg/m2/d d1-3 and paclitaxel 175 mg/m2 d1(week 9 and week 13).
Trial: NCT01591135
Drug: Cisplatin plus 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
Trial: NCT03150719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to TEZ/IVA fixed-dose combination tablet.
Trial: NCT03150719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to IVA tablet.
Trial: NCT00384618
Drug: pravastatin
RxNorm normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03657420
Drug: ABI-009
RxNorm normalized name: PICEA ABIES WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABI-009 is an mTOR inhibitor. This pathway is believed to be overactive in multiple myeloma.
Trial: NCT03005704
Drug: Antiplatelet treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with ticagrelor in combination with acetylsalicylic acid for five days. Ticagrelor will be administered at a loading dose of 180 mg, followed by 90 mg twice daily maintenance dose. Acetylsalicylic acid will be administered at a dose of 81 mg daily.
Trial: NCT00869622
Drug: Placebo + Calcium and Vitamin D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sugar pill + calcium 1200mgs/day and vitamin d at least 800IU
Trial: NCT01107522
Drug: CTO and Temodar®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of CTO daily for 28 day cycles, starting dose of CTO = 219 mg/m2.~Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.~Expansion Cohort of 6 patients on fixed dose of 600mg CTO/day Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle
Trial: NCT01107522
Drug: CTO, Temodar®, Radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of CTO daily for 28 day cycles; starting dose of CTO = 219 mg/m2 Temodar® administered orally at a dose of 75 mg/m2 daily during radiation therapy, then at 150mg/m2 for Days 1-5 of Cycle 1, and then up to 200 mg/m2 Days 1-5 of subsequent cycles Radiation: 3-dimensional conformal radiation therapy or, Radiation: intensity-modulated radiation therapy
Trial: NCT02183324
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02752243
Drug: CIK-Cells
RxNorm normalized name: Testone CIK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
Trial: NCT01285362
Drug: Placebo Supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
Trial: NCT01118741
Drug: Disulfiram
RxNorm normalized name: Disulfiram
DrugBank: Disulfiram (DB00822)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort 1: 250mg PO daily for 28 days Cohort 2: 500mg PO daily for 28 days
Trial: NCT05214690
Drug: DW1809-T2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pelubiprofen 25mg
Trial: NCT05214690
Drug: DW1809-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pelubiprofen 30mg (PELUBI tab.)
Trial: NCT01420068
Drug: SPP100
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03004638
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 3 doses of placebo matching with MEDI6012 intravenously (IV) on Days 1, 8, and 15.
Trial: NCT03004638
Drug: Placebo IV Push
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received 3 doses of placebo matching with MEDI6012 by IV push. A loading dose on Day 1 and maintenance doses on Days 3 and 10.
Trial: NCT01139775
Drug: LY2603618
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously as a continuous 1-hour infusion
Trial: NCT00365794
Drug: Topical testosterone gel 10 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone gel therapy for 20 weeks
Trial: NCT02707484
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were randomly assigned to receive a 120-days course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).
Trial: NCT02631642
Drug: HMPL-689
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selective PI3Kδ inhibitor
Trial: NCT02631642
Drug: HMPL-689 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo of HMPL-689
Trial: NCT02940756
Drug: artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).~One tablet twice daily for children weighing 5 to \<15 kg, two tablets twice daily for those weighing 15 to \<25 kg and three tablets twice daily for those weighing 25 to \< 35 kg, for three days.
Trial: NCT01061112
Drug: Flurbiprofen Control - Flurbiprofen Only
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 50 mg flurbiprofen dose taken at the start of the study period. No other drugs administered during this study period.
Trial: NCT01061112
Drug: Flurbiprofen Inhibition - Flurbiprofen & Fluconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 50 mg flurbiprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Trial: NCT01061112
Drug: Ketoprofen Control - Ketoprofen Only
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 75 mg ketoprofen dose taken at the start of the study period. No other drugs administered during this study period.
Trial: NCT01061112
Drug: Ketoprofen Inhibition - Ketoprofen & Fluconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single 75 mg ketoprofen dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Trial: NCT02473939
Drug: VR942 delivered via a Vectura Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02473939
Drug: Placebo delivered via a Vectura Dry Powder Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00020787
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose: 1000mg/m2/day Route: 24-hour continuous infusion in 0.9% NaCl over 5 days Schedule: Day 1 to Day 5 (5-day infusion) and then every 4 weeks
Trial: NCT02545959
Drug: methylprednisolone IV
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: blood infusion of methylprednisolone IV (120mg)
Trial: NCT04486937
Drug: S410914 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S410914 tablet
Trial: NCT01624571
Drug: LD02GIFRO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different dosages of drug
Trial: NCT04119297
Drug: Heparinoids Topical Cream
RxNorm normalized name: heparinoids Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Heparinoid cream was applied to the periorbital area once at 3rd and 9th hours following craniotomy, and 4 times daily in the following 3 days.~* Periorbital edema, upper and lower eyelid ecchymosis of the patients were evaluated on the 3rd and 9th hours after craniotomy, and on the 1st, 2nd and 3rd days (twice daily) using the Kara \& Gokalan's Scale
Trial: NCT00569972
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched oral placebo for weeks 2-7.
Trial: NCT01099618
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG \< 130mg/dL and A1c \<7%) during the 3-year follow-up period.
Trial: NCT00966992
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04124731
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Pemetrexed combined with platinum regimen (non-squamous cell carcinoma): pemetrexed 500mg/m2, intravenous infusion on the first day of each cycle, cisplatin 75mg/m2 or carboplatin AUC 5, intravenous infusion on the first day of each cycle, 1 cycle every 3 weeks (Q3W), 4 cycles in total. Patients who did not progress after 4 cycles received maintenance monotherapy with pemetrexide at the same dose as before.~2. Gemcitabine combined with platinum regimen (squamous cell carcinoma): gemcitabine 1250mg/m2, intravenous infusion on day 1 and day 8 of each cycle, cisplatin: 75mg/m2 or carboplatin: AUC 5, intravenous infusion on day 1 of each cycle, 1 cycle every 3 weeks (Q3W), 4-6 cycles in total.
Trial: NCT02965573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02095548
Drug: SM04690, 0.07mg/2mL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02095548
Drug: SM04690, 0.23mg/2mL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02095548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04503148
Drug: Inhaled General Anesthetics
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevoflurane or desflurane for induction and maintenance of anesthesia
Trial: NCT02173691
Drug: Placebo inhalation aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02173691
Drug: Placebo inhalation powder capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03187301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single dose
Trial: NCT03922308
Drug: SHP655
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive injection of SHP655.
Trial: NCT04291287
Drug: Antithrombotic Agent
RxNorm normalized name: ANTITHROMBOTIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine diphosphate (ADP) receptor antagonists (or P2Y12 inhibitors) therapy include:~* Clopidogrel (Plavix®)~* Prasugrel (Efient®)~* Ticagrelor (Brilique®)~DOACs therapy include:~* Apixaban (Eliquis®)~* Dabigatran (Pradaxa®)~* Edoxaban (Lixiana®)~* Rivaroxaban (Xarelto®).~Oral anticoagulant therapy (OAT) include:~* Warfarin (Counmadin®)~* Acenocumarol (Sintrom®)
Trial: NCT02158585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will match the lamotrigine dosage, frequency and duration.
Trial: NCT04089631
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 months capecitabine, in combination with oxaliplatin 3 to 6 months capecitabine
Trial: NCT01072773
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2, orally, on days 1, 8, 15 \& 22 every 28 days.
Trial: NCT02809729
Drug: sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline sterile by endovenous, once, at the moment of anesthetic induction
Trial: NCT04287660
Drug: clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * clarithromycin: 500mg, PO, twice daily, on days 1\~21 for a 28-day cycle.~* lenalidomide: 25mg, PO, on days 1\~21 for a 28-day cycle. dexamethasone: 40mg, PO on days 1,8,15 and 22 for a 28-day cycle. BCMA CAR T cell: (2-3)×10E7/kg, intravenously infusion.~* Doses should be adjusted according to renal function.
Trial: NCT04303689
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients with essential hypertension are randomized to receive either 3 weeks of placebo-treatment
Trial: NCT01047059
Drug: Fluoro-L-thymidine
RxNorm normalized name: L-thymidine
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: FLT-PET tracer for imaging
Trial: NCT01965756
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01256450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buccal soluble film; applied to the buccal mucosa twice daily
Trial: NCT00513981
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes